The treatment landscape for ALK+ metastatic non-small cell lung cancer (mNSCLC) is continuing to evolve, with durable outcomes from frontline ALK inhibition and emerging therapies offering new possibilities across disease settings. Join Dr. Angel Qin, Clinical Associate Professor of Internal Medicine at the University of Michigan Medical School, as she examines the evidence on current and emerging treatment options for this population.
Podden och tillhörande omslagsbild på den här sidan tillhör
ReachMD. Innehållet i podden är skapat av ReachMD och inte av,
eller tillsammans med, Poddtoppen.
